Bausch Health's (BHC) Q4 results on Feb. 19 will be mainly eyed by investors for the company's 2025 guidance, a potential full separation of Bausch + Lomb (BLCO), and upcoming debt maturities in Q4 this year, RBC Capital Markets said Thursday.
RBC said it expects Bausch Health to post Q4 revenue of $2.56 billion, above the FactSet consensus of $2.52 billion, and adjusted EBITDA of $918.8 million, below the FactSet consensus of $939 million.
For 2025, RBC expects Bausch Health to deliver revenue of $10.01 billion, above consensus at $9.9 billion, and adjusted EBITDA of $3.42 billion, in line with consensus forecasts.
Meanwhile, the investment firm said it trimmed Bausch Health's price target to $10 from $11 as it's decreasing the Bausch + Lomb sale scenario weighting to 60% from 75% after a media report saying that Blackstone (BX) will likely drop out of a consortium with TPG (TPG) to take out the eye care company.
A potential sale of Bausch + Lomb would result in about $6.5 billion to $7.7 billion in proceeds to Bausch Health, RBC said.
The investment firm has a sector perform rating on Bausch Health.
Price: 7.46, Change: -0.01, Percent Change: -0.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.